![Ami Knoefler](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ami Knoefler
Contatto Relazioni con gli Investitori presso ADAGENE INC.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Peizhi Luo | M | 59 | 13 anni | |
Yiu Leung Cheung | M | 64 | 3 anni | |
Mervyn Turner | M | 77 | 1 anni | |
Cuong Viet Do | M | 58 | 2 anni | |
Fang Yong Du | M | 55 | 12 anni | |
Man Kin Tam | M | 47 | 5 anni | |
Min Li | M | 62 | 3 anni | |
Songmao Zheng | M | - | 3 anni | |
Alexander Goergen | M | 38 | 7 anni | |
Ling Zhou | F | - | 5 anni | |
Dana Hu-Lowe | M | - | 3 anni | |
Charles R. Cantor | M | 81 |
Boston University
| 32 anni |
Gui Zhong Liu | M | 54 | 9 anni | |
Qing Hai Zhao | M | 64 | 4 anni | |
JC Xu | M | 60 | 4 anni | |
Yumeng Wang | F | 33 | 1 anni | |
Xiao Hong She | F | 58 | 13 anni | |
Jiping Zha | M | - | 3 anni | |
Chunfang Gu | F | - | 7 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Francis Sarena | M | 53 |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
Herbert Cross | M | 52 |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | - |
Faheem Hasnain | M | 65 |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
Bradford Goodwin | M | 69 |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
Cary L. Queen | M | 73 | 20 anni | |
Mitchell A. Garrison | M | - |
Boston University
| 8 anni |
Andrew M. Jacobson | M | - |
Boston University
| 3 anni |
Ramdas Rao | M | 59 |
Boston University
| 10 anni |
Lisa J. Lee-Hwong | M | - |
Boston University
| 8 anni |
Katherine O'Neil | F | - |
Boston University
| 5 anni |
Francis Han Joe Tjia | M | 59 |
Boston University
| 2 anni |
Petrus Halim | M | 54 |
Boston University
| 5 anni |
Yu Wen Liu | F | - | 1 anni | |
Reza Dehkordy Hamid Behnam | M | - |
Boston University
| 5 anni |
Minalkumar Patel | M | 52 |
Boston University
| 7 anni |
Mark McCamish | M | 72 |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
Yan Li | F | 50 | 13 anni | |
Imad Osama Abdul Rahim Asfour | M | 57 |
Boston University
| 3 anni |
Ran Zhang | M | 56 |
Boston University
| 4 anni |
Reem Haitham Jamil Goussous | F | 52 |
Boston University
| 6 anni |
Mohamed Sharara | M | - |
Boston University
| 5 anni |
Kartini Syahrir | M | 71 |
Boston University
| 4 anni |
Adam David Seitchik | M | - |
Boston University
| 4 anni |
Suzanne Hendrix | M | - |
Boston University
| 4 anni |
Cynthia Shumate | F | 62 | 4 anni | |
Mark McDade | M | 69 | 5 anni | |
Timothy E. Hawkins | M | - |
Boston University
| 9 anni |
Andrew Guggenhime | M | 55 |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
Luis R. Cortez | M | - |
Boston University
| 5 anni |
Jon Saxe | M | 88 | 19 anni | |
Peter H. Calcott | M | 75 | - | |
James Markarian | M | 57 |
Boston University
| 5 anni |
Nicola George Nicola Abu Khader | M | 53 |
Boston University
| 4 anni |
Dan Scherman | M | 62 |
Boston University
| 3 anni |
Rodney Small | M | - |
Boston University
| 4 anni |
Suhendro Bakri | M | 72 |
Boston University
| 1 anni |
Rich Kahn | M | - |
Boston University
| 5 anni |
Nicolay W. Del Salto | M | - |
Boston University
| 4 anni |
Paxton Kinol | M | - |
Boston University
| 4 anni |
Mariana Graciela Rodríguez Risco | F | - |
Boston University
| 2 anni |
Matthew Yu | M | - |
Boston University
| 4 anni |
Mark Notkin | M | - |
Boston University
| 2 anni |
Mark Adam Schiffenhaus | M | - |
Boston University
| 4 anni |
Leonard Jay Weinstein | M | - |
Boston University
| 4 anni |
Mousa Awni Mousa Al-Saket | M | 51 |
Boston University
| 4 anni |
Matt Eagan | M | - |
Boston University
| 4 anni |
Robert Rosen | M | 51 |
Boston University
| 4 anni |
Enrico Berton | M | 58 |
Boston University
| 4 anni |
Carlos Alberto Boggio Bertinet | M | - |
Boston University
| 4 anni |
Woo-Seok Jang | M | 53 |
Boston University
| 12 anni |
Ron Moraski | M | - |
Boston University
| 4 anni |
Scott Storrer | M | 56 |
Boston University
| 2 anni |
Dan Henderson | M | - |
Boston University
| 4 anni |
Jennifer E. Leonard | F | - |
Boston University
| 4 anni |
Wendy Nunez | F | - |
Boston University
| 4 anni |
Richard P. Milgram | M | - |
Boston University
| 4 anni |
Ralph J. Folz | M | - |
Boston University
| 1 anni |
Bryan Biniak | M | 55 |
Boston University
| 4 anni |
Raul R. Rai | M | - |
Boston University
| 4 anni |
Gregory Baldwin | M | - |
Boston University
| - |
Daniel Taub | M | 53 |
Boston University
| 4 anni |
Steven D. Girouard | M | - |
Boston University
| 4 anni |
Jon Glass | M | - |
Boston University
| 3 anni |
Patrick O'Brien | M | - |
Boston University
| 3 anni |
David Roland Rodgers | M | - |
Boston University
| 4 anni |
John M. Grady | M | - |
Boston University
| 6 anni |
Edgardo Khafif | M | 55 |
Boston University
| 4 anni |
Michael Francis McCaffery | M | - |
Boston University
| 4 anni |
Hans Fless | M | - |
Boston University
| 4 anni |
Douglas B. Grane | M | - |
Boston University
| 4 anni |
Patrick J. Callery | M | - |
Boston University
| 4 anni |
Scott Lake | M | - |
Boston University
| 2 anni |
Ann Peters | F | - |
Boston University
| 4 anni |
Eric D. Muller | M | - |
Boston University
| 4 anni |
James P. Galligan | M | - |
Boston University
| 4 anni |
Jeffrey Beck | M | 61 |
Boston University
| 2 anni |
Kimberly Ann Ratcliffe | F | 63 |
Boston University
| 2 anni |
Andrew Roskill | M | - |
Boston University
| 2 anni |
King Sau Mak | M | 51 |
Boston University
| 4 anni |
Susan Simi | F | - |
Boston University
| 6 anni |
John B. Duer | M | - |
Boston University
| 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 80 | 80.00% |
Cina | 20 | 20.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Ami Knoefler
- Contatti personali